* Athersys Inc ATHX.OQ ATHX.O is expected to report
results on May 4 (estimated).
*
* Refinitiv's mean analyst estimate for Athersys Inc is for
a
loss of 54 cents per share.
* The one available analyst rating on the shares is "buy".
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "Buy".
* Wall Street's median 12-month price target for Athersys
Inc is
$5.5, above its last closing price of $0.80.
This summary was machine generated May 2 at 17:32 GMT. All
figures in US dollars unless otherwise stated